Aktana Named Trailblazer in Commercial Analytics & AI Assessment by Everest Group

Aktana, the leader in intelligent customer engagement for the global life sciences industry, announced being named a trailblazer in Everest Group’s assessment report, “Life Sciences Commercial Analytics & AI Trailblazers.” The new report, issued last month, assessed 47 startups primarily on core capabilities and market impact, looking specifically at domain focus, market buzz, product capabilities, and human capital (talent and leadership). Aktana received the highest overall and tied for the highest rating in both domain focus and human capital.

Latest NaturalAI Insights: InspireXT Announces Acquisition Of NaturalAI – A Conversational Artificial Intelligence Platform To Expand Its Solution Portfolio

“Life Sciences Commercial Analytics & AI Trailblazers.”

“Aktana has been leading and defining the category for more than a decade,” said Derek Choy, president of Aktana. “Our exclusive focus on intelligent data activation for life sciences has enabled us to transform contextual engagement in healthcare and win recognition from important industry analysts, such as Everest Group, as well as grow market share.”

Aktana has emerged as a trailblazer in commercial life sciences analytics and AI from more than 300 deployments across 50+ use cases. More than half of the world’s top-20 pharmaceutical companies – including Novartis, GSK, Novo Nordisk, Merck, Sanofi, and Pfizer – rely on Aktana to coordinate and optimize personalized omnichannel engagement with HCPs. Aktana’s Contextual Intelligence 360 platform is powered by the company’s next-generation Contextual Intelligence Engine, which uses AI-driven optimization to predict the value of all potential customer experiences, then prioritize and recommend Next Best Engagements that will deliver the highest ROI.

AI News: Infobip Creates AI-powered Chatbot for Uber

“The focus on delivering hyper-personalized customer experience is pushing life sciences enterprises to transform their commercial technology landscape. Interestingly, start-ups and niche commercial technology providers are starting to gain significant mindshare with life sciences enterprises, as they make targeted bets to address whitespaces in the commercial technology domain with their unique domain and experience-centric IP and value proposition,” according to Chunky Satija, Vice President, Everest Group. “Aktana offers an AI-based platform and a suite of modular solutions to help life sciences enterprises with hyper-personalized customer engagement, customer journey management, and cognitive intelligence spanning the entire commercial function, thus resulting in it being featured as a trailblazer in Life Sciences Commercial Analytics & AI Trailblazers assessment.”

Everest Group’s Life Sciences Commercial Analytics & AI Trailblazers® assessment is based on two dimensions and multiple criteria:

• Market impact: Measures impact in the market via market adoption (number of customers, revenue base, year-over-year growth), portfolio mix (diversity of customer base) and value delivered to customer based on customer feedback and other measures.
• Core capability: Measures ability to deliver products successfully via five sub-dimensions, including vision and strategy; technology capability; flexibility and ease of deployment; engagement and commercial model; and support.

Aktana’s modular solution enables commercial and medical teams from all-sized organizations to rapidly scale AI programs to personalize, optimize, and coordinate HCP engagement across channels and teams – allowing customers to grow sales by up to 15%.

Latest Aithority Insights : NVIDIA Raises the Standard of Low Code DevOps with the NVIDIA AI Enterprise 2.1

 [To share your insights with us, please write to sghosh@martechseries.com]